Tempus Study Finds AI Prescreening Achieved Over 80% Biomarker Sensitivity

Tempus said its AI-enabled prescreening panel achieved greater than 80% sensitivity across all 12 biomarkers assessed in a study of advanced non-small cell lung cancer patients, exceeding 90% for several biomarkers.